Navigation Links
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
Date:4/17/2008

SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) presented a late-breaker oral presentation today at the 21st International Conference on Antiviral Research (ICAR) in Montreal, Quebec, providing updated preclinical data on ANA598, a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5b polymerase.

The presentation reported several preclinical attributes of ANA598 that support the potential for beneficial combination of the product candidate with several other anti-HCV agents. Specifically, ANA598 was reported to be highly synergistic with interferon-alpha and non-antagonistic with ribavirin in cell-based assays. Furthermore, ANA598 retained full activity against a number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be used in combination with multiple other anti-HCV agents, regardless of class.

Anadys also presented the pharmacokinetic (PK) profile of ANA598 based on the results of 28-day toxicology studies. An oral dose of 20 mg/kg in monkeys provided plasma levels of ANA598 at 12 hours that were in excess of the protein-binding adjusted genotype 1a replicon EC95, suggesting the potential for twice-daily or once-daily dosing. In addition, ANA598 was tolerated in all preclinical studies up to the maximum doses tested.

"The preclinical PK profile combined with the previously reported potency of the agent provides further confidence that ANA598 will be an active antiviral in HCV infected patients," said James Freddo, M.D., Chief Medical Officer of Anadys. "The in vitro combination dat
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... RALEIGH, N.C., Nov. 15, 2010 PRA International, a ... experts will lead a panel at the 9th annual ... 17-18 November 2010. PRA, a co-sponsor of the conference, ... Stansfield, Executive Vice President of PRA,s Product Registration group ...
... 2010 The Radiology journal released new ... women with newly diagnosed breast cancer that shows Positron ... study found that PEM was significantly more precise at ... "Positive Predictive Value" or "PPV," therefore reducing the number ...
Cached Medicine Technology:PRA International Expert to Chair Panel at Partnerships Conference 2Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI 2
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Smithsonian Whistleblower and Asbestos Experts to Dispute Smithsonian,s ... Safe for Workers and Public WASHINGTON, March 16 ... press conference on Tuesday, March 17, to announce ... the U.S. Office of Special Counsel. In ...
... Inc. (NYSE: WLP ) has placed No. ... Diversity(R) list, which was announced last week by DiversityInc.A ... from last year, vied for the honor this year, ... companies. "In its fourth year participating, WellPoint demonstrates the ...
... Children,s National Medical Center and colleagues in Tokyo publish results, video ... , ... Washington, DC (PRWEB) March 16, 2009 -- Genetic ... Center of Neurology and Psychiatry in Tokyo published the results of ...
... maintain a healthy weight and who have lower perceived ... associated with aging than obese and stressed women, according ... Sister Study. The long-term Sister Study is looking at ... had breast cancer to identify factors associated with developing ...
... Uninsured, including those who are recently unemployed, can attend ... expertPITTSBURGH, March 16 As the nation marks National ... Highmark is offering resources to help Pennsylvanians without health ... the Pennsylvania Insurance Department found that the uninsured ranks ...
... key, however, experts say, , , MONDAY, March 16 (HealthDay ... and tools have significantly improved the management of this ... in the mid-,90s, children with severe asthma during 2004 ... and rescue inhalers, and their lung function scores were ...
Cached Medicine News:Health News:Smithsonian Worker Exposed to Asbestos Files Whistleblower Retaliation Complaint 2Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 2Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 3Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 4Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 2Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 3Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 4Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 5Health News:First sister study results reinforce the importance of healthy living 2Health News:First sister study results reinforce the importance of healthy living 3Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 2Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 3Health News:New Treatments Improve Control for Severe Asthma 2Health News:New Treatments Improve Control for Severe Asthma 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: